[Federal Register: January 23, 2002 (Volume 67, Number 15)]
[Page 3219]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on January 30, 2002, from 9 
a.m. to 5 p.m.
    Location: Holiday Inn, Versailles I and II, 8120 Wisconsin Ave., 
Bethesda, MD.
    Contact: William Freas or Denise H. Royster, Center for Biologics 
Evaluation and Research (HFM-71), Food and Drug Administration, 1401 
Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12391. Please call the Information Line for 
up-to-date information on this meeting.
    Agenda: On January 30, 2002, the committee will discuss the 
influenza virus vaccine formulation for the 2002-2003 season.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by January 22, 
2002. Oral presentations from the public will be scheduled between 
approximately 9:30 a.m. and 9:45 a.m., and approximately 4:15 p.m. and 
5 p.m. Time allotted for each presentation may be limited. Those 
desiring to make formal oral presentations should notify the contact 
person before January 22, 2002, and submit a brief statement of the 
general nature of the evidence or arguments they wish to present, the 
names and addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation.
    FDA regrets that it was unable to publish this notice 15 days prior 
to the Vaccines and Related Biological Products Advisory Committee 
meeting. Because the agency believes there is some urgency to bring 
this issue to public discussion and qualified members of the Vaccines 
and Related Biological Products Advisory Committee were available at 
this time, the Commissioner of Food and Drugs concluded that it was in 
the public interest to hold this meeting even if there was not 
sufficient time for the customary 15-day public notice.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: January 17, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 02-1713 Filed 1-18-02; 1:52 pm]